Fluvastatin
featured

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H317900

CAS#: 93957-54-1 (free acid)

Description: Fluvastatin belongs to a class of medications called statins and is used to reduce plasma cholesterol levels and prevent cardiovascular disease. It is also the first entirely synthetic HMG-CoA reductase inhibitor and is structurally distinct from the fungal derivatives of this therapeutic class.

Chemical Structure

img
Fluvastatin
CAS# 93957-54-1 (free acid)
Instruction

Theoretical Analysis

Hodoodo Cat#: H317900
Name: Fluvastatin
CAS#: 93957-54-1 (free acid)
Chemical Formula: C24H26FNO4
Exact Mass: 411.18
Molecular Weight: 411.466
Elemental Analysis: C, 70.06; H, 6.37; F, 4.62; N, 3.40; O, 15.55

Price and Availability

Size Price Availability Quantity
10mg USD 250 2 Weeks
25mg USD 450 2 Weeks
50mg USD 850 2 Weeks
Bulk inquiry

Related CAS #: 93957-55-2 (sodium)   94061-81-1 (sodium)   93957-54-1 (free acid)   500103-16-2 (calcium)   1009811-63-5 (potassium)    

Synonym: Fluvastatin, Lescol, Canef, Vastin, Cranoc, XU-62320

IUPAC/Chemical Name: (E,3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid

InChi Key: FJLGEFLZQAZZCD-MCBHFWOFSA-N

InChi Code: InChI=1S/C24H26FNO4/c1-15(2)26-21-6-4-3-5-20(21)24(16-7-9-17(25)10-8-16)22(26)12-11-18(27)13-19(28)14-23(29)30/h3-12,15,18-19,27-28H,13-14H2,1-2H3,(H,29,30)/b12-11+/t18-,19-/m1/s1

SMILES Code: O=C(O)C[C@H](O)C[C@H](O)/C=C/C(N1C(C)C)=C(C2=CC=C(F)C=C2)C3=C1C=CC=C3

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 411.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Janić M, Lunder M, Šabovič M. A low-dose combination of fluvastatin and valsartan: a new "drug" and a new approach for decreasing the arterial age. Biomed Res Int. 2015;2015:235709. doi: 10.1155/2015/235709. Epub 2015 Mar 3. Review. PubMed PMID: 25821790; PubMed Central PMCID: PMC4363554.

2: Voûte MT, Winkel TA, Poldermans D. Safety of fluvastatin in patients undergoing high-risk non-cardiac surgery. Expert Opin Drug Saf. 2010 Sep;9(5):793-800. doi: 10.1517/14740338.2010.499120. Review. PubMed PMID: 20557267.

3: Neuvonen PJ, Backman JT, Niemi M. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. Clin Pharmacokinet. 2008;47(7):463-74. Review. PubMed PMID: 18563955.

4: Stein EA, Corsini A, Gimpelewicz CR, Bortolini M, Gil M. Fluvastatin treatment is not associated with an increased incidence of cancer. Int J Clin Pract. 2006 Sep;60(9):1028-34. Review. PubMed PMID: 16939542.

5: Holdaas H, Wanner C, Abletshauser C, Gimpelewicz C, Isaacsohn J. The effect of fluvastatin on cardiac outcomes in patients with moderate to severe renal insufficiency: a pooled analysis of double-blind, randomized trials. Int J Cardiol. 2007 Apr 12;117(1):64-74. Epub 2006 Aug 4. Review. PubMed PMID: 16889855.

6: Chan MY, Lee CH. Fluvastatin: efficacy and safety in reducing cardiac events. Expert Opin Pharmacother. 2005 Sep;6(11):1883-95. Review. PubMed PMID: 16144508.

7: Corsini A, Holdaas H. Fluvastatin in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation. Ren Fail. 2005;27(3):259-73. Review. PubMed PMID: 15957541.

8: Liberopoulos EN, Daskalopoulou SS, Mikhailidis DP, Wierzbicki AS, Elisaf MS. A review of the lipid-related effects of fluvastatin. Curr Med Res Opin. 2005 Feb;21(2):231-44. Review. PubMed PMID: 15801994.

9: Corsini A. The use of statins in optimising reduction of cardiovascular risk: focus on fluvastatin. Int J Clin Pract. 2004 May;58(5):494-503. Review. PubMed PMID: 15206507.

10: Corsini A, Jacobson TA, Ballantyne CM. Fluvastatin: clinical and safety profile. Drugs. 2004;64(12):1305-23. Review. PubMed PMID: 15200346.

11: Tysk C, Al-Eryani AY, Shawabkeh AA. Acute pancreatitis induced by fluvastatin therapy. J Clin Gastroenterol. 2002 Nov-Dec;35(5):406-8. Review. PubMed PMID: 12394230.

12: Langtry HD, Markham A. Fluvastatin: a review of its use in lipid disorders. Drugs. 1999 Apr;57(4):583-606. Review. Erratum in: Drugs 1999 Sep;58(3):404. PubMed PMID: 10235694.

13: Garnett WR. A review of current clinical findings with fluvastatin. Am J Cardiol. 1996 Sep 26;78(6A):20-5. Review. PubMed PMID: 8875971.

14: Plosker GL, Wagstaff AJ. Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia. Drugs. 1996 Mar;51(3):433-59. Review. PubMed PMID: 8882381.

15: Peters TK. Treatment of dyslipidaemias with fluvastatin. Br J Clin Pract Suppl. 1996 Jan;77A:16-9. Review. PubMed PMID: 8729585.

16: Baggio G. [An update on the use of fluvastatin in primary hypercholesterolemia]. Ann Ital Med Int. 1995 Oct;10 Suppl:43S. Review. Italian. PubMed PMID: 8562264.

17: Jokubaitis LA. Updated clinical safety experience with fluvastatin. Am J Cardiol. 1994 May 26;73(14):18D-24D. Review. PubMed PMID: 8198019.

18: Levy RI, Troendle AJ, Fattu JM. A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin. Circulation. 1993 Apr;87(4 Suppl):III45-53. Review. PubMed PMID: 8462180.

19: McDonald KJ, Jardine AG. The use of fluvastatin in cardiovascular risk management. Expert Opin Pharmacother. 2008 Jun;9(8):1407-14. doi: 10.1517/14656566.9.8.1407 . Review. PubMed PMID: 18473714.

20: Asberg A, Holdaas H. Fluvastatin and fluvastatin extended release: a clinical and safety profile. Expert Rev Cardiovasc Ther. 2004 Sep;2(5):641-52. Review. PubMed PMID: 15350166.